Jeanine R Gore, MD
Family Practice · San Mateo
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Gore’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A156169 · Current
Licensed to practise in California · since 2018 · expires 2028-03-31 · University of California, Davis School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$54,667
Medicare paid this office $54,667 for 368 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 190 | $21,849 | $105 |
| New patient visit (45+ min) | 50 | $7,354 | $147 |
| Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | 44 | $6,290 | $140 |
| Short return visit (20+ min) | 78 | $5,401 | $65 |
| Long return visit (40+ min) | 23 | $4,268 | $164 |
See all 13 services
| Return visit (30+ min) | 190 | $21,849 | $105 |
| New patient visit (45+ min) | 50 | $7,354 | $147 |
| Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | 44 | $6,290 | $140 |
| Short return visit (20+ min) | 78 | $5,401 | $65 |
| Long return visit (40+ min) | 23 | $4,268 | $164 |
| New patient visit (30+ min) | 36 | $3,228 | $90 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 22 | $1,106 | $50 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 32 | $518 | $16 |
| Insertion of needle into vein for collection of blood sample | 38 | $355 | $9 |
| Injection of drug or substance under skin or into muscle | 17 | $241 | $14 |
| Automated urinalysis test | 64 | $143 | $2 |
| Inhalation treatment for airway obstruction or sputum production | 14 | $103 | $7 |
| Injection, ceftriaxone sodium, per 250 mg | 14 | $21 | None |
Procedures Medicare counted
| Removal of tissue | 1-10 | None |
Who their Medicare patients are
368 Original Medicare patients in 2024. Average age 76 · Under 65 4% · 85 and older 16% · Women 65% · Also on Medicaid 4% · Health risk score 0.93. At or below the middle of the specialty; the typical family practice clinician is at 1.13.
Conditions among them: High blood pressure 65% · Coronary heart disease 21% · Diabetes 19% · Chronic kidney disease 17% · Cancer 16% · Atrial fibrillation 15% · Depression 15% · COPD 10% · Heart failure 9% · Dementia 4% · Stroke 4%.
The office billed $190,330, Medicare allowed $74,761 and paid $54,667; for 794 services of 47 kinds; $33 of it was for drugs given in the office and $54,634 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 368 | 794 | 76 | 0.93 | $190,330 | $54,667 |
| 2023 | 432 | 905 | 77 | 1.03 | $209,924 | $63,893 |
| 2022 | 433 | 851 | 77 | 0.99 | $192,855 | $56,784 |
| 2021 | 336 | 612 | 77 | 1.12 | $134,046 | $39,841 |
| 2020 | 128 | 193 | 77 | 1.11 | $44,093 | $12,184 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 15 services
| Return visit (30+ min) | 236 | $29,144 | $114 |
| Short return visit (20+ min) | 126 | $11,154 | $79 |
| New patient visit (45+ min) | 41 | $6,042 | $147 |
| New patient visit (30+ min) | 45 | $3,787 | $84 |
| Detection test by multiplex amplified probe technique for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (covid-19), influenza virus types a and b, and respiratory syncytial virus | 23 | $3,215 | $140 |
| Long return visit (40+ min) | 20 | $3,194 | $160 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 41 | $2,112 | $50 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 33 | $551 | $16 |
| Insertion of needle into vein for collection of blood sample | 40 | $336 | $8 |
| Detection test by immunoassay with direct visual observation for influenza virus | 13 | $243 | $16 |
| Injection of drug or substance under skin or into muscle | 12 | $197 | $14 |
| Automated urinalysis test | 80 | $187 | $2 |
| Inhalation treatment for airway obstruction or sputum production | 15 | $157 | $10 |
| Blood creatinine level | 16 | $80 | $5 |
| Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 15 | $2 | None |
2022: 13 services
| Return visit (30+ min) | 135 | $16,855 | $114 |
| New patient visit (30+ min) | 110 | $10,464 | $95 |
| New patient visit (45+ min) | 69 | $9,330 | $135 |
| Short return visit (20+ min) | 112 | $8,593 | $72 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 70 | $3,593 | $51 |
| Long return visit (40+ min) | 16 | $2,254 | $141 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 28 | $456 | $16 |
| Detection test by immunoassay with direct visual observation for influenza virus | 15 | $244 | $16 |
| Insertion of needle into vein for collection of blood sample | 65 | $202 | $3 |
| Injection of drug or substance under skin or into muscle | 14 | $197 | $14 |
| Inhalation treatment for airway obstruction or sputum production | 11 | $131 | $12 |
| Automated urinalysis test | 52 | $118 | $2 |
| Blood creatinine level | 12 | $61 | $5 |
2021: 10 services
| Return visit (30+ min) | 141 | $15,649 | $107 |
| Short return visit (20+ min) | 104 | $8,530 | $76 |
| Long return visit (40+ min) | 22 | $3,739 | $170 |
| New patient visit (30+ min) | 34 | $2,655 | $78 |
| Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | 43 | $2,206 | $51 |
| New patient visit (45+ min) | 21 | $2,145 | $102 |
| Detection test by immunoassay with direct visual observation for streptococcus, group a (strep) | 15 | $248 | $17 |
| Injection of drug or substance under skin or into muscle | 12 | $179 | $14 |
| Automated urinalysis test | 51 | $115 | $2 |
| Insertion of needle into vein for collection of blood sample | 30 | $90 | $3 |
2020: 5 services
| Return visit (30+ min) | 60 | $5,873 | $98 |
| Short return visit (20+ min) | 41 | $2,732 | $62 |
| New patient visit (30+ min) | 23 | $2,095 | $91 |
| Insertion of needle into vein for collection of blood sample | 13 | $37 | $3 |
| Automated urinalysis test | 15 | $32 | $2 |
Medicaid work
$367 in 2021
Medicaid paid $367 for 24 billed services this clinician did in 2021, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 24 | $367 |
| 2021 | 24 | 1 | 12 | $367 |
Drugs they prescribed that Part D paid
$8,914
Pharmacies billed $8,914 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
305 generic and fewer than 11 brand-name prescriptions · $8,914 in drug cost · 162 antibiotic prescriptions to 142 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Paxlovid | 13 | $1,382 | $106 |
| Albuterol Sulfate Hfa | 30 | $726 | $24 |
| Amoxicillin-Clavulanate Potass | 32 | $263 | $8 |
| Doxycycline Monohydrate | 37 | $219 | $6 |
| Mupirocin | 13 | $126 | $8 |
See all 8 drugs
| Paxlovid | 13 | $1,382 | $106 |
| Albuterol Sulfate Hfa | 30 | $726 | $24 |
| Amoxicillin-Clavulanate Potass | 32 | $263 | $8 |
| Doxycycline Monohydrate | 37 | $219 | $6 |
| Mupirocin | 13 | $126 | $8 |
| Cephalexin | 24 | $123 | $5 |
| Cefadroxil | 12 | $74 | $6 |
| Prednisone | 16 | $44 | $3 |
Year by year
| 2024 | 360 | 251 | None | None | $8,914 |
| 2023 | 414 | 297 | 4% (15) | 10% | $8,321 |
| 2022 | 325 | 226 | None | 6% | $5,518 |
| 2021 | 210 | 169 | None | None | $3,072 |
| 2020 | 131 | 89 | None | 16% | $2,818 |
| 2019 | 198 | 48 | None | None | $12,775 |
| 2018 | 95 | 33 | None | None | $7,435 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Albuterol Sulfate Hfa | 33 | $736 | $22 |
| Doxycycline Monohydrate | 28 | $414 | $15 |
| Amoxicillin-Clavulanate Potass | 38 | $393 | $10 |
| Paxlovid (Eua) | 33 | $346 | $10 |
| Cephalexin | 50 | $323 | $6 |
| Fluticasone Propionate | 15 | $211 | $14 |
| Valacyclovir | 11 | $190 | $17 |
| Nitrofurantoin Mono-Macro | 12 | $127 | $11 |
| Mupirocin | 19 | $104 | $5 |
| Azithromycin | 13 | $75 | $6 |
| Fluconazole | 11 | $48 | $4 |
| Sulfamethoxazole-Trimethoprim | 14 | $46 | $3 |
| Prednisone | 11 | $31 | $3 |
2022: 10 drugs
| Albuterol Sulfate Hfa | 16 | $600 | $38 |
| Amoxicillin-Clavulanate Potass | 28 | $310 | $11 |
| Cephalexin | 30 | $273 | $9 |
| Paxlovid (Eua) | 20 | $209 | $10 |
| Mupirocin | 24 | $208 | $9 |
| Doxycycline Monohydrate | 12 | $166 | $14 |
| Azithromycin | 21 | $148 | $7 |
| Ciprofloxacin | 13 | $147 | $11 |
| Valacyclovir | 13 | $141 | $11 |
| Prednisone | 26 | $77 | $3 |
2021: 5 drugs
| Amoxicillin-Clavulanate Potass | 22 | $222 | $10 |
| Cephalexin | 35 | $221 | $6 |
| Nitrofurantoin Mono-Macro | 13 | $175 | $13 |
| Mupirocin | 18 | $174 | $10 |
| Azithromycin | 11 | $74 | $7 |
2020: 1 drug
| Cephalexin | 11 | $81 | $7 |
2019: 2 drugs
| Amlodipine Besylate | 18 | $123 | $7 |
| Losartan | 11 | $63 | $6 |
Professional record
- NPI
- 1730592148
- Licence
- CA A156169California A156169: Current · expires 2028-03-31
- Trained
- University of California, Davis School of Medicine, 2015
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 261QU0200X (261QU0200X); Family medicine (207Q00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2014-06-04
- NPI last updated
- 2026-07-07
- NPI record certified
- 2026-07-07
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 4400 U St, Sacramento, CA, 95817